{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:24:06Z","timestamp":1780507446591,"version":"3.54.1"},"reference-count":46,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Sickle cell disease (SCD) is a hematological disorder that primarily affects individuals of African descent from sub-Saharan Africa and along the mediterranean. The main complications leading to hospitalizations include vaso-occlusive crises (VOCs) and acute chest syndrome (ACS). Therefore, the main objective of this paper was to identify and evaluate evidence-based management and prevention of VOCs in patients with SCD. A literature search of PubMed, Medline Cochrane and Google Scholar database (January 1985 to April 2020) was performed using the following search terms \u201cvaso-occlusive crises\u201d, \u201csickle cell disease\u201d, \u201chydroxyurea\u201d, \u201cL-glutamine\u201d, \u201cvoxelotor\u201d, \u201ccrizanlizumab\u201d, \u201ctreatment\u201d and \u201cprevention\u201d as well as a combination of these terms. All English-language interventional studies assessing the efficacy and safety of VOC outcomes were evaluated. Literature was excluded if published in a language other than English or if it was a review article. A total of 69 articles were identified and there were 7 articles that met the search criteria. Majority of the studies focused on mean and median annual rates of VOCs as primary outcomes while median time to first sickle cell crises, median rates of hospitalizations etc were evaluated as secondary outcomes. After reviewing the literature, many patients with VOCs will still benefit from hydroxyurea therapy since long term efficacy data and cost is still a concern for the newer agents including L-glutamine, voxelotor and crizanlizumab. Other factors such as cost or compliance may also be taken into consideration when making recommendations for therapy.<\/jats:p>","DOI":"10.1177\/08971900211026644","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T05:44:51Z","timestamp":1624254291000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0935-7957","authenticated-orcid":false,"given":"Salome Bwayo","family":"Weaver","sequence":"first","affiliation":[{"name":"Howard University College of Pharmacy, Clinical Administrative & Pharmacy Sciences, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhakrit","family":"Rungkitwattanakul","sequence":"additional","affiliation":[{"name":"Howard University College of Pharmacy, Clinical Administrative & Pharmacy Sciences, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divita","family":"Singh","sequence":"additional","affiliation":[{"name":"Howard University College of Pharmacy, Clinical Administrative & Pharmacy Sciences, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"bibr1-08971900211026644","unstructured":"Sickle Cell Disease (SCD). Centers for disease control and prevention. Published December 16, 2020. Accessed April 1, 2021. www.cdc.gov\/ncbddd\/sicklecell\/data.html"},{"key":"bibr2-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1080\/17434440.2016.1254038"},{"key":"bibr3-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21443"},{"key":"bibr4-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21408"},{"key":"bibr5-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.10517"},{"key":"bibr6-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865"},{"key":"bibr7-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1542\/pir.33.5.195"},{"key":"bibr8-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2013.09.006"},{"key":"bibr9-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011783"},{"key":"bibr10-08971900211026644","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-155-1-201107050-00002","volume":"155","author":"Steinbert M","year":"2011","journal-title":"Ann Intern Med"},{"key":"bibr11-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107043250103"},{"key":"bibr12-08971900211026644","volume-title":"Guidelines for Standard of Care of Acute Painful Episodes in Patients with Sickle Cell Disease","author":"Ballis SK","year":"1996"},{"key":"bibr13-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08317.x"},{"issue":"5","key":"bibr14-08971900211026644","first-page":"358","volume":"23","author":"Ballas SK","year":"1993","journal-title":"Ann Clin Lab Sci"},{"issue":"5","key":"bibr15-08971900211026644","first-page":"1349","volume":"61","author":"Yale SH","year":"2000","journal-title":"Am Fam Physician"},{"key":"bibr16-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(16)36735-9"},{"key":"bibr17-08971900211026644","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"bibr18-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1088827"},{"key":"bibr19-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-008318"},{"key":"bibr20-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3173132.x"},{"key":"bibr21-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-146852"},{"key":"bibr22-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"bibr23-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221333"},{"key":"bibr24-08971900211026644","unstructured":"ENDARI (L-glutamine oral powder) [package insert]. Torrance, CA: Emmaus Medical, Inc. Published 2017. Revised July, 2017. Accessed April 1, 2021. https:\/\/www.endarirx.com\/pi."},{"key":"bibr25-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.2.512.512"},{"key":"bibr26-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1159\/000063062"},{"key":"bibr27-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2143(97)90062-7"},{"key":"bibr28-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V"},{"key":"bibr29-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971"},{"key":"bibr30-08971900211026644","unstructured":"Oxbryta (volexotor tablets) [package insert]. South San Francisco, CA: Global Blood Therapeutics, Inc. Published 2019. Revised November 2019. Accessed April 1, 2021. https:\/\/hcp.oxbryta.com\/pdf\/prescribing-information.pdf"},{"issue":"2","key":"bibr31-08971900211026644","first-page":"e7105","volume":"12","author":"Salma MA","year":"2020","journal-title":"Cureus"},{"key":"bibr32-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868893"},{"key":"bibr33-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212"},{"key":"bibr34-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129026"},{"key":"bibr35-08971900211026644","unstructured":"ADAKVEO (crizanlizumab-tmca) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. Published 2019. Revised November, 2019. Accessed April 1, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761128s000lbl.pdf"},{"key":"bibr36-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1955"},{"key":"bibr37-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0626"},{"key":"bibr38-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0713"},{"key":"bibr39-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.211615"},{"key":"bibr40-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052522799"},{"key":"bibr41-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"bibr42-08971900211026644","unstructured":"Wiley F. New sickle cell drugs give hope, but access remains a barrier. Hematology News. Published March 19, 2020. Accessed June 14, 2021. https:\/\/www.mdedge.com\/hematology-oncology\/article\/219361\/anemia\/new-sickle-cell-drugs-give-hope-access-remains-barrier#:\u223c:text=In%20a%202017%20CNBC%20interview,i%20the%20neighborhood%20of%20%24100%2C000"},{"key":"bibr43-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001851"},{"key":"bibr44-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001143"},{"key":"bibr45-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001142"},{"key":"bibr46-08971900211026644","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000916"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900211026644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900211026644","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900211026644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:48Z","timestamp":1777509408000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900211026644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1177\/08971900211026644"],"URL":"https:\/\/doi.org\/10.1177\/08971900211026644","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}